Conatus Pharma Q3 Loss Widens - Quick Facts

(RTTNews) - Conatus Pharmaceuticals (CNAT) posted third-quarter net loss applicable to common stockholders of $3.3 million, wider than $2.6 million in the comparable quarter last year. Loss per share for the latest third quarter was $0.28, narrower than $2.55 last year.

On average, four analysts polled by Thomson Reuters expected the company to report a loss of $0.27 per share.

Research and development expenses were $1.9 million, compared with $1.8 million last year, while general and administrative expenses were $1.1 million, up from $0.7 million in the year-ago period.